search
Back to results

Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options

Primary Purpose

Diabetes Mellitus, Type 1

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
gastric emptying test
gut hormones determination
Continuous Glucose Monitoring
Insulin single bolus
Insulin double-wave bolus
Sponsored by
Federico II University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 1 focused on measuring Type 1 Diabetes mellitus, Gastric Emptying, Insulin Infusion Pump

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • DM1;
  • Use of insulin pump;
  • Disease duration ≥ 3 years.

Exclusion Criteria:

  • Presence of chronic complications of DM (including cardiovascular autonomic neuropathy);
  • BMI ≥ 30 kg/m2;
  • Presence of chronic diseases other than DM1;
  • Diseases that interfere with GE;
  • Medications that interfere with blood glucose homeostasis (except insulin) and GE.

Sites / Locations

  • Dept. of "Medicina Clinica e Chirurgia" of Federico II UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Cases

Controls

Arm Description

gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus

gastric emptying test gut hormones determination

Outcomes

Primary Outcome Measures

gastric emptying measure

Secondary Outcome Measures

gut hormones dosage
Continuous Glucose Monitoring
postprandial glucose variability after single insulin bolus
postprandial glucose variability after double-wave insulin bolus

Full Information

First Posted
February 4, 2015
Last Updated
February 18, 2015
Sponsor
Federico II University
search

1. Study Identification

Unique Protocol Identification Number
NCT02365740
Brief Title
Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options
Official Title
Postprandial Blood Glucose Control and Gastric Emptying in Patients With Type 1 Diabetes: Pathogenetic Factors, Clinical Relevance and Possible Therapeutic Options
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Unknown status
Study Start Date
November 2014 (undefined)
Primary Completion Date
November 2015 (Anticipated)
Study Completion Date
November 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federico II University

4. Oversight

5. Study Description

Brief Summary
This study evaluates the prevalence of gastric emptying (GE) in type 1 diabetic patients (DM1) free of chronic complications in comparison with a group of healthy control subjects. The investigators will also assess the relationship between GE and glucose control (HbA1c, postprandial glucose variability), gut peptide hormones (GLP-1, GIP, and ghrelin), and gastrointestinal symptoms. In addition, in patients with delayed GE the investigators will investigate the effect of "tailored" pre-prandial insulin bolus administered by means of insulin pump in reducing postprandial glucose variability, evaluated through continuous glucose monitoring system.
Detailed Description
Diabetic patients with a delayed GE will be studied in 2 separate occasions in euglycemic condition and under CGM. On both occasions, they will have to take a standard meal poor of lipids (rice 60 g; yellow squash 200 g; extra virgin olive oil 7 g; adult veal lean cuts 90 g; bananas 180 g; ordinary bread 75 g). On the first occasion pre-prandial insulin will be administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load. On the second occasion the amount of pre-prandial insulin will be the same as the first one test but fractioned into a double-wave bolus. The "tailored" insulin bolus will be defined according to the individual pattern of GE, as follows: GE T1/2 121-180 min= 60% as bolus + 40% during following 2 h GE T1/2 >180 min= 40% as bolus + 60% during following 4 h Glycemic variability will be assessed by the means of Continuous Glucose Monitoring System and the following indexes of glucose variability will be calculated: number of hypoglycemic events, number of hyperglycemic events, standard deviation of glycemia, glycemia variation coefficient, mean range of daily glycemia, interquartile range, M value, mean amplitude of glycemic excursions (MAGE), low blood glucose index (LBGI), high blood glucose index (HBGI).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1
Keywords
Type 1 Diabetes mellitus, Gastric Emptying, Insulin Infusion Pump

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cases
Arm Type
Experimental
Arm Description
gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus
Arm Title
Controls
Arm Type
Sham Comparator
Arm Description
gastric emptying test gut hormones determination
Intervention Type
Other
Intervention Name(s)
gastric emptying test
Intervention Description
gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
Intervention Type
Other
Intervention Name(s)
gut hormones determination
Intervention Description
blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
Intervention Type
Other
Intervention Name(s)
Continuous Glucose Monitoring
Intervention Description
7 days Continuous Glucose Monitoring
Intervention Type
Drug
Intervention Name(s)
Insulin single bolus
Intervention Description
pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
Intervention Type
Drug
Intervention Name(s)
Insulin double-wave bolus
Intervention Description
pre-prandial insulin fractioned into a double-wave bolus
Primary Outcome Measure Information:
Title
gastric emptying measure
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
gut hormones dosage
Time Frame
3 hours
Title
Continuous Glucose Monitoring
Time Frame
7 days
Title
postprandial glucose variability after single insulin bolus
Time Frame
3 hours
Title
postprandial glucose variability after double-wave insulin bolus
Time Frame
3 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: DM1; Use of insulin pump; Disease duration ≥ 3 years. Exclusion Criteria: Presence of chronic complications of DM (including cardiovascular autonomic neuropathy); BMI ≥ 30 kg/m2; Presence of chronic diseases other than DM1; Diseases that interfere with GE; Medications that interfere with blood glucose homeostasis (except insulin) and GE.
Facility Information:
Facility Name
Dept. of "Medicina Clinica e Chirurgia" of Federico II University
City
Naples
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brunella Capaldo, MD
Phone
0817462311
Email
bcapaldo@unina.it
First Name & Middle Initial & Last Name & Degree
Roberta Lupoli, MD
Phone
0817462427
Email
sereroby@yahoo.it
First Name & Middle Initial & Last Name & Degree
Brunella Capaldo, MD
First Name & Middle Initial & Last Name & Degree
Roberta Lupoli, MD
First Name & Middle Initial & Last Name & Degree
Lutgarda Bozzetto, MD
First Name & Middle Initial & Last Name & Degree
Giovanni Annuzzi, MD

12. IPD Sharing Statement

Learn more about this trial

Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options

We'll reach out to this number within 24 hrs